Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Expert Opinion on Drug Metabolism & Toxicology|May 19, 2011
Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugsKimie Sai, Yoshiro Saito
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|April 2, 2008
[Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A1*6 and *28]Kimie Sai, Jun-ichi Sawada, Hironobu Minami
International Journal of Clinical Pharmacy|March 31, 2015
Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patientsTadaaki Hanatani, Kimie Sai, Masahiro Tohkin, et al.
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyujo Hokoku = Bulletin of National Institute of Health Sciences|December 19, 2012
[Trends in drug-induced liver injury based on reports of adverse reactions to PMDA in Japan]Chie Sudo, Keiko Maekawa, Katsunori Segawa, et al.
Biological & Pharmaceutical Bulletin|September 5, 2017
Influence of Japanese Regulatory Action on Denosumab-Related Hypocalcemia Using Japanese Adverse Drug Event Report DatabaseMayu Takeyama, Kimie Sai, Takuya Imatoh, et al.
Cancer Science|September 10, 2010
Modulation of RIP1 ubiquitylation and distribution by MeBS to sensitize cancer cells to tumor necrosis factor α-induced apoptosisSeungseob Kim, Nobumichi Ohoka, Keiichiro Okuhira, et al.
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyujo Hokoku = Bulletin of National Institute of Health Sciences|January 21, 2012
[Current movements of four serious adverse events induced by medicinal drugs based on spontaneous reports in Japan]Chie Sudo, Yu-ichiro Azuma, Keiko Maekawa, et al.
Therapeutic Innovation & Regulatory Science|January 4, 2021
Efficacy Comparison for a Schizophrenia and a Dysuria Drug Among East Asian Populations: A Retrospective Analysis Using Multi-regional Clinical Trial DataKimie Sai, Eiji Nakatani, Yasuhiro Iwama, et al.
Pageof 7